NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free BNTX Stock Alerts $92.72 +0.48 (+0.52%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$91.60▼$93.5050-Day Range$86.17▼$96.3052-Week Range$85.21▼$125.83Volume661,736 shsAverage Volume654,446 shsMarket Capitalization$22.04 billionP/E Ratio22.50Dividend YieldN/APrice Target$120.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.30 Rating ScoreUpside/Downside29.9% Upside$120.40 Price TargetShort InterestBearish1.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.74) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector2299th out of 5,430 stocksBiological Products, Except Diagnostic Industry304th out of 903 stocks 4.2 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.33% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in BioNTech has recently increased by 2.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 1.4 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioNTech this week, compared to 8 articles on an average week.Search InterestOnly 11 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -66% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -93% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($1.74) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 22.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.90.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 22.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 259.19.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesMay 3, 2024 | seekingalpha.comBioNTech: Undecided Between A One Trick Pony And A Full-Fledged Pharma CompanyMay 3, 2024 | seekingalpha.comBioNTech Earnings Preview: I Will Stay On The SidelinesMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 29, 2024 | americanbankingnews.comBioNTech (BNTX) to Release Earnings on MondayApril 26, 2024 | msn.comCOVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent BattleApril 25, 2024 | msn.comWhat's Going On With Pfizer Stock On Thursday?April 25, 2024 | msn.comGSK sues Pfizer, BioNTech over COVID-19 vaccines patentsApril 25, 2024 | reuters.comGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technologyMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 22, 2024 | globenewswire.comBioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024April 17, 2024 | markets.businessinsider.comAssessing BioNTech: Insights From 11 Financial AnalystsApril 7, 2024 | globenewswire.comThree-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic CancerMarch 31, 2024 | investorplace.comThe 3 Best Bargain Stocks to Buy in Q2 2024March 26, 2024 | investorplace.com3 Biotech Stocks to Buy for the Next Bull Run: March 2024March 26, 2024 | finance.yahoo.comThis Vaccine Maker Sits on Cash Almost Equal to Its Market ValueMarch 25, 2024 | markets.businessinsider.comOptimistic Outlook for BioNTech: A Buy Rating Amidst Vaccine Demand and Strong Oncology PipelineMarch 24, 2024 | finance.yahoo.comBioNTech Full Year 2023 Earnings: Misses ExpectationsMarch 23, 2024 | finance.yahoo.comEarnings Miss: BioNTech SE Missed EPS By 14% And Analysts Are Revising Their ForecastsMarch 22, 2024 | msn.comBioNTech Tumbles as Q4 Profit, Sales Trail Estimates on Falling COVID-19 Vaccine DemandMarch 21, 2024 | msn.comWhy Is BioNTech Stock Trading Lower On Wednesday?March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Edwards Lifesciences (EW) and Innovent Biologics (OtherIVBXF)March 21, 2024 | markets.businessinsider.comHold Rating for BioNTech: Navigating Vaccine Revenue Decline and Prospective Oncology PipelineMarch 21, 2024 | finance.yahoo.comBioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comMaintaining Hold on BioNTech: A Balancing Act Between Near-Term Challenges and Long-Term Oncology InvestmentMarch 20, 2024 | msn.comBioNTech slides as earnings plunge amid cancer drug shiftMarch 20, 2024 | seekingalpha.comPfizer partner BioNTech ekes out Q4 profit despite 65% revenue dropMarch 20, 2024 | finance.yahoo.comBioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter FinancialsSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/04/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$120.40 High Stock Price Target$171.00 Low Stock Price Target$90.00 Potential Upside/Downside+29.9%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$4.12 Trailing P/E Ratio22.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins24.26% Pretax Margin31.06% Return on Equity4.60% Return on Assets4.12% Debt Debt-to-Equity Ratio0.01 Current Ratio9.43 Quick Ratio9.26 Sales & Book Value Annual Sales$4.13 billion Price / Sales5.33 Cash Flow$5.23 per share Price / Cash Flow17.74 Book Value$92.17 per share Price / Book1.01Miscellaneous Outstanding Shares237,730,000Free Float192,083,000Market Cap$22.04 billion OptionableOptionable Beta0.25 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.23MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $809.78kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.42MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $832.18kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.02MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $803.38kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $601.73kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXNeurocrine BiosciencesNASDAQ:NBIXBiogenNASDAQ:BIIBBio-TechneNASDAQ:TECHQiagenNYSE:QGENView All CompetitorsInstitutional OwnershipLester Murray Antman dba SimplyRichBought 721 shares on 5/4/2024Ownership: 0.001%Baillie Gifford & Co.Sold 330,243 shares on 5/1/2024Ownership: 3.516%Mirae Asset Global Investments Co. Ltd.Bought 31,615 shares on 5/1/2024Ownership: 0.029%Janney Montgomery Scott LLCBought 3,404 shares on 5/1/2024Ownership: 0.001%Capstone Investment Advisors LLCBought 2,855 shares on 5/1/2024Ownership: 0.001%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech SE is actively developing a range of innovative immunotherapies for cancer and infectious diseases, showcasing a strong pipeline of product candidates. The company's FixVac product candidates, such as BNT122 in Phase II clinical trials for first-line melanoma and multiple solid tumors, demonstrate promising potential in addressing unmet medical needs. BioNTech SE has established collaborations with reputable partners like Genentech, Pfizer, and Sanofi, enhancing its research capabilities and market reach. With ongoing clinical trials for various cancers like prostate, ovarian, and lung cancer, BioNTech SE is positioned to make significant advancements in cancer treatment, potentially leading to increased market value. Considering the current stock price and the company's robust development pipeline, investing in BioNTech SE could offer long-term growth opportunities for investors. Cons Investors should be bearish about investing in BioNTech SE for these reasons: Despite the promising pipeline, the biotechnology industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring products to market successfully. Ongoing clinical trials carry inherent risks, including potential setbacks or failures, which could lead to delays in product approvals and revenue generation. The success of BioNTech SE's product candidates is not guaranteed, and any setbacks in clinical trials or regulatory approvals could negatively affect the company's financial performance and stock value. Investing in biotechnology companies like BioNTech SE involves high volatility due to market sentiment, regulatory changes, and scientific uncertainties, which may not align with all investors' risk tolerance levels. While the company has collaborations with industry leaders, partnership dynamics and outcomes are subject to change, impacting BioNTech SE's research priorities and market positioning. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com. BNTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price target for 2024? 10 analysts have issued twelve-month price targets for BioNTech's stock. Their BNTX share price targets range from $90.00 to $171.00. On average, they anticipate the company's share price to reach $120.40 in the next twelve months. This suggests a possible upside of 29.9% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2024? BioNTech's stock was trading at $105.54 on January 1st, 2024. Since then, BNTX shares have decreased by 12.1% and is now trading at $92.72. View the best growth stocks for 2024 here. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our BNTX earnings forecast. How can I listen to BioNTech's earnings call? BioNTech will be holding an earnings conference call on Monday, May 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) announced its quarterly earnings results on Wednesday, March, 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.64 by $0.59. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a net margin of 24.26% and a trailing twelve-month return on equity of 4.60%. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Morningstar US Small Growth (MSGR), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB), Virtus LifeSci Biotech Products ETF (BBP) and Franklin Genomic Advancements ETF (HELX). What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.52%), Simplex Trading LLC (0.00%), IMC Chicago LLC (0.00%), Van ECK Associates Corp (0.05%), Mirae Asset Global Investments Co. Ltd. (0.03%) and China Universal Asset Management Co. Ltd. (0.01%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More This page (NASDAQ:BNTX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.